Cosmos Health forecasts over $6 million in annual U.S. revenue from Oliv18 within 12-18 months

• Cosmos Health forecast Oliv18 to add over $6 million in annual U.S. revenue within 12-18 months.
• Outlook implies about $4.3 million in gross profit, based on an expected gross margin of about 72%.
• Rollout starts with direct-to-consumer e-commerce, followed by expansion into selected retail channels.
• Model assumes pricing, sales volumes, repeat purchases, distribution growth tied to execution of commercialization plans.
• Target markets: U.S. cardiovascular supplements $2.11 billion in 2024, projected $3.27 billion by 2030; antioxidants $1.66 billion in 2025, projected $3.18 billion by 2035.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608241540OMX_____CNEWS_EN_GNW9815111_en) on August 24, 2026, and is solely responsible for the information contained therein.